The COVID-19 pandemic has led to financial hardship for a number of pediatricians around the country. The American Academy of Pediatrics (AAP) says that some relief is finally on the way.
In April, the American Academy of Pediatrics (AAP) called on the Department of Health and Human Services (HHS) to provide financial relief to practices that were struggling to meet monetary obligations because of COVID-19. On June 9, 2020, HHS responded and said that monetary aid was finally on the way.
In a letter to AAP members, president Sara H. Goza, MD, FAAP, announced the HHS’s plan, assured members that AAP was going to continue to advocate for them, and said that they would be reaching out to members over the next few days to cover eligibility status and also provide step-by-step instructions on how to get the financial help.1
Not all of the plan’s specifics are known, but there AAP shared the following:
Reference:
1. Goza SH. New financial relief available for pediatricians: message from the AAP president. Published June 9, 2020. Accessed June 10, 2020. https://contentsharing.net/actions/email_web_version.cfm?ep=9baoVVftuXoWPkminnrpb1RHcz64U-ClaQF5yuMwRycm9ka_thzgxI99d5uwJUJW0zN6HEr1RwT46wiFTAv1OV-WOmSp79KxNEPgQwA-YRk82MLaDDYxJARJV1PXzeiaaU0xeGFLxZw-hAnAXc-25g~~
CDC recommends nirsevimab be prioritized for highest-risk infants amid limited availability
October 26th 2023The Centers for Disease Control and Prevention is advising providers to prioritize 100 mg doses of nirsevimab, a monoclonal antibody FDA-approved to prevent respiratory syncytial virus (RSV), for infants at the highest risk of severe RSV disease.
Navigating a complex case of pediatric COVID-19 with immunomodulatory therapies
October 21st 2023Eculizumab and anakinra should be considered in critically ill patients with severe infections that require immunomodulating therapies for life-threatening dysregulation, according to a poster session at the 2023 American Academy of Pediatrics National Conference & Exhibition.